GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
तुलना करने के लिए मीट्रिक्स | 2160 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध2160पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 23.9x | −7.2x | −0.6x | |
PEG अनुपात | 0.07 | −0.31 | 0.00 | |
क़ीमत/बुक | 5.2x | 4.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 7.6x | 69.6x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 16.5% | 37.7% | 52.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 9.5% | 8.4% | अनलॉक करें |